(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-0.01%) $82.62
(0.79%) $2.05
(-0.54%) $2 345.00
(-1.03%) $27.38
(-0.28%) $958.80
(0.08%) $0.933
(0.13%) $11.00
(0.01%) $0.796
(1.56%) $93.31
1.51% $ 82.13
@ $82.88
Ausgestellt: 29 Apr 2024 @ 20:37
Rendite: -0.90%
Vorheriges Signal: Apr 29 - 15:33
Vorheriges Signal:
Rendite: 0.99 %
Live Chart Being Loaded With Signals
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease...
Stats | |
---|---|
Tagesvolumen | 1.92M |
Durchschnittsvolumen | 1.55M |
Marktkapitalisierung | 15.59B |
EPS | $0 ( 2024-04-24 ) |
Nächstes Ertragsdatum | ( $0.610 ) 2024-07-29 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 77.48 |
ATR14 | $2.40 (2.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-12 | Bienaime Jean Jacques | Buy | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Common Stock |
2024-04-11 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
2024-04-12 | Bienaime Jean Jacques | Sell | 20 000 | Stock Option (Right to Buy Common Stock) |
INSIDER POWER |
---|
25.84 |
Last 93 transactions |
Buy: 972 265 | Sell: 563 201 |
Volumen Korrelation
Biomarin Pharmaceutical Korrelation
10 Am meisten positiv korreliert | |
---|---|
MMAC | 0.923 |
RMRM | 0.916 |
FREQ | 0.89 |
ABST | 0.889 |
IMPL | 0.889 |
SGBX | 0.887 |
TTOO | 0.887 |
INFI | 0.885 |
SBBP | 0.884 |
CFV | 0.884 |
10 Am meisten negativ korreliert | |
---|---|
APOP | -0.956 |
ICON | -0.907 |
RDUS | -0.893 |
MIND | -0.88 |
TRMD | -0.879 |
WRLD | -0.878 |
SYKE | -0.875 |
SOUN | -0.873 |
MGTX | -0.873 |
FEYE | -0.869 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Biomarin Pharmaceutical Korrelation - Währung/Rohstoff
Biomarin Pharmaceutical Finanzdaten
Annual | 2023 |
Umsatz: | $2.42B |
Bruttogewinn: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2023 |
Umsatz: | $2.42B |
Bruttogewinn: | $1.84B (76.15 %) |
EPS: | $0.890 |
FY | 2022 |
Umsatz: | $2.10B |
Bruttogewinn: | $1.61B (76.92 %) |
EPS: | $0.760 |
FY | 2021 |
Umsatz: | $1.85B |
Bruttogewinn: | $1.38B (74.52 %) |
EPS: | $-0.354 |
Financial Reports:
No articles found.
Biomarin Pharmaceutical
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.